[Control of the emesis induced by cisplatin in patients with head and neck neoplasms. Randomized study of metoclopramide alizapride and placebo].
A double blind study has been lead on 75 patients affected by head and neck cancer treated with CDDP, to verify the alizapride's antiemetic efficacy versus placebo and metoclopramide. On 76 patients examined, 28 has been treated with CDDP 50 mg/mq + alizapride; 28 with CDDP 50 mg/mq + metoclopramide and finally 19 with CDDP 50 mg/mq + placebo. Both alizapride and metoclopramide administered have resulted effective on the control of the emesis induced with CDDP without side effects.
Istituto di Clinica Otorinolaringoiatrica, Università degli Studi di Catania.
A
A
Denaro
M
M
Rossi
A
A
Garozzo
M
M
Matera
V
V
Neri
D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D004341:Drug Evaluation; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D011759:Pyrrolidines; D008787:Metoclopramide; C033968:alizapride; D002945:Cisplatin
Controllo dell'emesi indotta da cisplatino in pazienti con tumori della testa e del collo. Studio randomizzato fra metoclopramide alizapride e placebo.